You can probably recite the GLP-1 benefits in your sleep by now. Ozempic, Wegovy, Zepbound. We know them for weight loss. For diabetes control. But the list keeps getting longer. Migraine severity? Down. Alzheimer’s prevention? Maybe. Now it’s skin. Specifically psoriasis. That chronic, itchy, autoimmune condition where your body attacks healthy cells because it simply forgot what healthy looks like.
Scientists think these gut drugs might calm it down.
“GLP-1 medications appear have benefits beyond weight loss and diabetes controls,” says Samip Sheth. He is the lead study author and resident at the University of Minnesota’s departments of Dermatology and Internal Medicine.
The logic follows the inflammation. Psoriasis loves inflammation. So does obesity. So does type 2 diabetes.
Here’s who’s weighing in. Gary Goldenberg, an assistant clinical professor at Icahn School of Mount Sinai. Ife J. Rodney from Eternal Dermatology in Florida. Cindy Wassef in New Jersey. And Dr. Sheth again, obviously.
What the numbers say
A review landed in JAMA Dermatology. The data looks interesting. Patients taking GLP-1 agonists saw their symptoms drop. Redness faded. Patch coverage shrunk. We are talking improvements ranging from 40% to 80%.
Those with extra weight or diabetes did best. Makes sense. They had the most to lose, metabolically speaking.
But take it with salt. Or at least skepticism. Most of these studies were small. Short term. No control group to compare against.
The researchers admit it isn’t perfect yet. We need bigger trials.
“GLP-1 agonists may have a role beyond their uses.”
Why the itch might fade
So why would a drug for your belly help your back? Experts have theories. None of them are fully proven but all make biological sense.
Ife J. Rodney says these drugs simply turn down the volume on systemic inflammation. Psoriasis is not just a skin disease, she argues. It is whole-body inflammation manifesting outwardly.
Cindy Wassef points to specific proteins. IL-17. These are inflammatory messengers. GLP-1 drugs lower IL-17 levels. Other psoriasis meds target these exact same proteins. It’s a overlap of targets.
Gary Goldenberg focuses on fat. Specifically the visceral kind. The stuff around your organs.
GLP-1 drugs cause significant weight loss. Less fat tissue means fewer inflammatory signals flooding the blood. The drivers of the rash quiet down. That explains why the diabetics and those with obesity saw the biggest changes.
Where this is going
Should you ask your doctor for a prescription just for your eczema? Not yet.
We aren’t there. Doctors won’t officially approve these drugs for skin issues anytime soon. But the door is open. It’s a possibility for the future, especially if you juggle weight and diabetes with the psoriasis.
We have only scratched the surface, says Wassef. The research is just beginning.
More data will come. Maybe it helps. Maybe it doesn’t change how we treat skin disease.
Who knows. The science moves slow. The hype moves fast. Let’s see which one is right.
